Correction to: Rheumatol Ther (2023) 10:1459–1477 https://doi.org/10.1007/s40744-023-00601-w

This note aims to correct minor errors to the summarized DORIS (Definition of Remission in SLE) remission data from the referenced Morand et al. (Ann Rheum Dis. 2023) article. A correction was recently made to Morand et al. (2023) which updated the DORIS remission analyses to align with the published DORIS remission definition in van Vollenhoven et al. (Lupus Med Sci. 2021) by excluding only the serologic laboratory parameters from clinical SLEDAI-2K (cSLEDAI-2K). The original analyses of DORIS remission excluded all laboratory parameters from the calculation of cSLEDAI-2K. These updates do not change the conclusions of the findings. Changes are summarised below:

The definition of DORIS was corrected in the section titled, Past: Defining Remission and Low Disease Activity in SLE. The sentence beginning ‘DORIS remission is defined…’ should have read ‘DORIS remission is defined as achieving a clinical SLEDAI-2K = 0 and a Physician’s Global Assessment (PGA) < 0.5, irrespective of serology, with permitted use of antimalarials, low-dose glucocorticoids (GCs; prednisolone ≤ 5 mg/day), and/or stable doses of immunosuppressants, including biologics (Table 1) [7].’

The definition of DORIS was incorrect in Table 1 and in the “b” footnotes of Tables 2 and 3. The text is corrected as follows.

In Table 1 of this article, the wording ‘Stable immunosuppressant biologics’ in the column headed ‘DORIS remission [7]’ was unclear and should have been ‘Stable doses of immunosuppressants, including biologics’.

In Table 2 of this article, the note b was incorrect as ‘bDORIS 2021 criteria were defined as: clinical SLEDAI-2 = 0, PGA < 0.5 (0–3), irrespective of serology, permitted with use of antimalarials, low-dose GCs (prednisone-equivalent ≤ 5 mg/day), and/or stable immunosuppressives including biologics [7]’ and should have been ‘bDORIS 2021 criteria were defined as: clinical SLEDAI-2K = 0 and PGA < 0.5 (0–3), irrespective of serology, and permitted use of antimalarials, low-dose GCs (prednisolone-equivalent ≤ 5 mg/day), and/or stable immunosuppressants, including biologics [7]’.

The note b in Table 3 was incorrect as ‘bDORIS 2021 criteria were defined as: clinical SLEDAI-2K = 0, PGA < 0.5 (0–3), irrespective of serology, permitted with use of antimalarials, low-dose GCs (prednisone-equivalent ≤ 5 mg/day), and/or stable immunosuppressives including biologics [7]’ and should have been ‘bDORIS 2021 criteria were defined as: clinical SLEDAI-2K = 0 and PGA < 0.5 (0–3), irrespective of serology, and permitted use of antimalarials, low-dose GCs (prednisolone-equivalent ≤ 5 mg/day), and/or stable immunosuppressants, including biologics [7]’.

In Table 3 of this article, the DORIS remission data for the pooled TULIP-1/TULIP-2 studies were updated. The number and percentage of patients achieving DORIS remission in the placebo group changed from 28 and 7.6% to 24 and 6.6%; DORIS achievement in the anifrolumab group was unchanged. The odds ratio (95% confidence interval) and P-value for the comparison between the treatment groups were updated from 2.2 (1.4–3.6), P = 0.0013 to 2.6 (1.6–4.3), P = 0.0002. The excerpt from Table 3 is provided here.

Excerpt from Table 3

Table 3 DORIS remission and LLDAS outcomes in SLE RCTs
Full size table

In the sentence beginning ‘Patients treated with anifrolumab…’, under the section titled Present: Applying DORIS Remission and LLDAS Definitions, the DORIS definition was incorrect and should have been ‘Patients treated with anifrolumab spent more cumulative time in remission thresholds of ≥ 20% (OR [95% CI]: 2.2 [1.3–3.7]) and ≥ 50% (2.7 [1.0–7.0]) and were more likely to be in sustained remission for at least 3, 5, or 7 consecutive monthly visits (2.4 [1.4–3.9]), 3.0 [1.5–6.1], or 2.6 [1.1–6.4], respectively) [33].’

The original article has been corrected.